HPV Vaccine Approval Expanded Through Age 45

​ In a step crucial to preventing the occurrence of both the human papillomavirus (HPV) and HPV-related cancers, the United States Food and Drug Administration (FDA) has expanded the approval of the 9-valent human papillomavirus (9vHPV) vaccine (Gardasil®9, Merck and Co.) for men and women between the ages of 27 and 45. The human papillomavirus infects approximately 14 million Americans each year. It is also a well-documented cause of a number of cancers, including cervical carcinoma and orophar...
Continue reading

BAP1 Promotes Tumor Suppression Via Ferroptosis

Research performed at The University of Texas MD Anderson Cancer Center shows a potential new area of cancer therapy through the examination of BRCA-associated protein 1 (BAP1), a tumor suppressor gene in kidney, eye, bile duct, mesothelioma, and other cancers. BAP1 encodes a key enzyme which results in a type of cell death called ferroptosis. The team, led by Boyi Gan, PhD, associate professor at the Department of Experimental Radiation Oncology, identified a BAP1-mediated epigenetic mechanism ...
Continue reading

Curing Post-Radiation Dry Mouth

New research, led by Amy Wong of University of Arizona, suggests a method for repairing salivary glands after radiation damage. In patients with head-and-neck cancer, treatment from radiation often leaves the salivary glands damaged and unable to function properly, leading to major quality-of-life issues such as loss of the abilities to swallow, produce saliva, and protect the mouth from infection. Unfortunately, this damage is permanent, and patients do not recover function over time. "When you...
Continue reading

Expanding Range of Biomarkers for Immune Checkpoint Therapy

Recent research conducted at the Dana-Farber Cancer Institute and published in Nature Genetics has provided new biomarkers for predicting the efficacy of immune checkpoint inhibitors. Despite existing knowledge of biomarkers such as tumor mutational burden and wide clinical success across many cancer types, oncologists still face difficulty in gauging which patients will respond to immune checkpoint inhibitors and which will show resistance. Previous studies that sought to explore additional bio...
Continue reading

Throat, Not Cervix, Is Now Most Common HPV-Linked Cancer Site

According to a new report published by the Centers for Disease Control and Prevention (CDC), oropharyngeal squamous cell carcinoma (SCC), a cancer of the throat, has replaced cervical carcinoma as the cancer most commonly associated with human papillomavirus (HPV). Human papillomavirus, the most commonly sexually transmitted infection in the United States, is a known cause of cervical cancer and some types of oropharyngeal, vaginal, vulvar, penile, and anal cancers. According to the CDC report, ...
Continue reading
© Copyright 2018 i3 Health. All rights reserved.